JP2021536453A5 - - Google Patents

Info

Publication number
JP2021536453A5
JP2021536453A5 JP2021510807A JP2021510807A JP2021536453A5 JP 2021536453 A5 JP2021536453 A5 JP 2021536453A5 JP 2021510807 A JP2021510807 A JP 2021510807A JP 2021510807 A JP2021510807 A JP 2021510807A JP 2021536453 A5 JP2021536453 A5 JP 2021536453A5
Authority
JP
Japan
Prior art keywords
dosage form
lumateperone
form according
monotosylate
agent
Prior art date
Application number
JP2021510807A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021536453A (ja
JPWO2020047407A5 (https=
JP7546546B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/049061 external-priority patent/WO2020047407A1/en
Publication of JP2021536453A publication Critical patent/JP2021536453A/ja
Publication of JPWO2020047407A5 publication Critical patent/JPWO2020047407A5/ja
Publication of JP2021536453A5 publication Critical patent/JP2021536453A5/ja
Application granted granted Critical
Publication of JP7546546B2 publication Critical patent/JP7546546B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021510807A 2018-08-31 2019-08-30 新規方法 Active JP7546546B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862725944P 2018-08-31 2018-08-31
US62/725,944 2018-08-31
US201862779920P 2018-12-14 2018-12-14
US62/779,920 2018-12-14
PCT/US2019/049061 WO2020047407A1 (en) 2018-08-31 2019-08-30 Novel methods

Publications (4)

Publication Number Publication Date
JP2021536453A JP2021536453A (ja) 2021-12-27
JPWO2020047407A5 JPWO2020047407A5 (https=) 2022-09-06
JP2021536453A5 true JP2021536453A5 (https=) 2022-09-06
JP7546546B2 JP7546546B2 (ja) 2024-09-06

Family

ID=69644650

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021510807A Active JP7546546B2 (ja) 2018-08-31 2019-08-30 新規方法

Country Status (11)

Country Link
US (3) US11957791B2 (https=)
EP (1) EP3843738A4 (https=)
JP (1) JP7546546B2 (https=)
KR (2) KR20260011198A (https=)
CN (1) CN112584837A (https=)
AU (2) AU2019328528B2 (https=)
BR (1) BR112021003655A2 (https=)
CA (1) CA3108553A1 (https=)
IL (1) IL280912A (https=)
MX (1) MX2021002322A (https=)
WO (1) WO2020047407A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013155504A1 (en) 2012-04-14 2013-10-17 Intra-Cellular Therapies, Inc. Novel methods
EP4001281A1 (en) 2016-08-09 2022-05-25 Teva Pharmaceuticals International GmbH Solid state forms of lumateperone ditosylate salt and preparation thereof
US11331316B2 (en) 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
IL268970B2 (en) 2017-03-24 2023-12-01 Intra Cellular Therapies Inc Oral transmucosal formulations of substituted heterocycle fused gamma carbolines
CN111107847A (zh) 2017-09-26 2020-05-05 细胞内治疗公司 新的盐和晶体
WO2019178484A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
CA3108558A1 (en) * 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
CN112584837A (zh) * 2018-08-31 2021-03-30 细胞内治疗公司 新方法
MX2021006886A (es) * 2018-12-14 2021-09-14 Intra Cellular Therapies Inc Dispersiones solidas amorfas.
WO2020132605A1 (en) 2018-12-21 2020-06-25 Intra-Cellular Therapies, Inc. Organic compounds
EP4034119A4 (en) * 2019-09-25 2023-10-18 Intra-Cellular Therapies, Inc. NOVEL METHODS
US12102636B2 (en) 2021-02-11 2024-10-01 Medtronic, Inc. Administration of antipsychotics
EP4469052A4 (en) * 2022-01-27 2026-02-11 Intra Cellular Therapies Inc NEW COMPOSITIONS
CN116919907A (zh) * 2022-04-01 2023-10-24 万特制药(海南)有限公司 一种卢美哌隆口崩片及其制备方法
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
EP4678165A1 (en) * 2023-03-03 2026-01-14 Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. Long-acting and sustained-release preparation composition of lumateperone and preparation method therefor
WO2025240804A1 (en) 2024-05-16 2025-11-20 Intra-Cellular Therapies, Inc. Novel compositions, devices and methods
WO2025240802A1 (en) * 2024-05-16 2025-11-20 Intra-Cellular Therapies, Inc. Novel compositions, devices and methods
CN118557536B (zh) * 2024-07-30 2024-11-15 山东则正医药技术有限公司 一种卢美哌隆口崩片组合物及其制备方法和应用

Family Cites Families (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1960534A (en) 1932-05-16 1934-05-29 James J Gibney Floodlight
US2490813A (en) 1944-11-29 1949-12-13 Standard Oil Co Continuous process for making aryl amines
US3299078A (en) 1962-10-01 1967-01-17 Smith Kline French Lab Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines
US3813392A (en) 1969-06-09 1974-05-28 J Sellstedt Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds
US4183936A (en) 1972-06-19 1980-01-15 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US3914421A (en) 1972-06-19 1975-10-21 Endo Lab Pyridopyrrolobenzheterocycles for combatting depression
US4115577A (en) 1972-06-19 1978-09-19 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4238607A (en) 1972-06-19 1980-12-09 Endo Laboratories Inc. Pyridopyrrolo benzheterocycles
US4001263A (en) 1974-04-01 1977-01-04 Pfizer Inc. 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines
IE41352B1 (en) 1974-04-01 1979-12-19 Pfizer 5-aryl-1,2,3,4-tetrahydro- -carbolines
US4136145A (en) 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
US4219550A (en) 1978-11-09 1980-08-26 E. I. Du Pont De Nemours And Company Cis- and trans- octahydropyridopyrrolobenzheterocycles
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4522944A (en) 1982-12-23 1985-06-11 Erba Farmitalia Carboxamido-derivatives of 5H-1,3,4-thiadiazolo[3,2-a]pyrimidines, compositions and use
CH656884A5 (de) 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
ATE59289T1 (de) 1985-10-09 1991-01-15 Desitin Arzneimittel Gmbh Verfahren zur herstellung einer darreichungsund dosierungsform fuer arzneimittel-wirkstoffe, reagentien oder andere wirkstoffe.
ES2058068T3 (es) 1986-03-19 1994-11-01 Kumiai Chemical Industry Co Derivados de 5h-1,3,4-tiadiazol-(3,2-a)-pirimidin-5-ona y compuestos fungicidas con contenido en dichos derivados.
EP0242690B1 (en) 1986-04-07 1993-06-30 Kumiai Chemical Industry Co., Ltd. 5H-1,3,4-Thiadiazolo[3,2-a]pyrimidin-5-one derivatives and agricultural-horticultural fungicide composition containing the same
HU208484B (en) 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
DE4018247A1 (de) 1990-06-07 1991-12-12 Lohmann Therapie Syst Lts Herstellungsverfahren fuer schnellzerfallende folienfoermige darreichungsformen
IT1271352B (it) 1993-04-08 1997-05-27 Boehringer Ingelheim Italia Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale
CN1074923C (zh) 1993-11-19 2001-11-21 詹森药业有限公司 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
JP4099224B2 (ja) 1994-03-02 2008-06-11 ナームローゼ・フエンノートチヤツプ・オルガノン 舌下又はバッカル医薬組成物
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US5576460A (en) 1994-07-27 1996-11-19 Massachusetts Institute Of Technology Preparation of arylamines
US5654482A (en) 1996-02-29 1997-08-05 Xerox Corporation Triarylamine processes
US5648539A (en) 1996-02-29 1997-07-15 Xerox Corporation Low temperature arylamine processes
US5648542A (en) 1996-02-29 1997-07-15 Xerox Corporation Arylamine processes
US5847166A (en) 1996-10-10 1998-12-08 Massachusetts Institute Of Technology Synthesis of aryl ethers
DE19646392A1 (de) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
US5723669A (en) 1997-01-30 1998-03-03 Xerox Corporation Arylamine processes
US5705697A (en) 1997-01-30 1998-01-06 Xerox Corporation Arylamine processes
US5723671A (en) 1997-01-30 1998-03-03 Xerox Corporation Arylamine processes
TWI242011B (en) 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
US6323366B1 (en) 1997-07-29 2001-11-27 Massachusetts Institute Of Technology Arylamine synthesis
GB2328686B (en) 1997-08-25 2001-09-26 Sankio Chemical Co Ltd Method for producing arylamine
US6884429B2 (en) 1997-09-05 2005-04-26 Isotechnika International Inc. Medical devices incorporating deuterated rapamycin for controlled delivery thereof
US6395939B1 (en) 1997-10-06 2002-05-28 Massachusetts Institute Of Technology Diaryl ether condensation reactions
US6235936B1 (en) 1998-02-26 2001-05-22 Massachusetts Institute Of Technology Metal-catalyzed arylations of hydrazines, hydrazones, and related substrates
WO1999043643A2 (en) 1998-02-26 1999-09-02 Massachusetts Institute Of Technology Metal-catalyzed arylations and vinylations of hydrazines, hydrazones, hydroxylamines and oximes
US5902901A (en) 1998-05-07 1999-05-11 Xerox Corporation Arylamine processes
US6395916B1 (en) 1998-07-10 2002-05-28 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
EP1097158B1 (en) 1998-07-10 2006-01-25 Massachusetts Institute Of Technology Ligands for metals and metal-catalyzed processes
US6307087B1 (en) 1998-07-10 2001-10-23 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US7223879B2 (en) 1998-07-10 2007-05-29 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US20010008942A1 (en) 1998-12-08 2001-07-19 Buchwald Stephen L. Synthesis of aryl ethers
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
WO2000035419A2 (en) 1998-12-17 2000-06-22 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
NO309305B1 (no) 1999-02-19 2001-01-15 Norsk Hydro As Anvendelse av benzaldehydderivater ved fremstilling av farmasöytiske preparater for forebygging og/eller behandling av kreft, samt visse nye benzaldehydderivater
US6407092B1 (en) 1999-04-23 2002-06-18 Pharmacia & Upjohn Company Tetracyclic azepinoindole compounds
PE20010052A1 (es) 1999-04-23 2001-01-27 Upjohn Co Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
MXPA01012969A (es) 1999-06-15 2003-10-14 Bristol Myers Squibb Pharma Co Gamma-carbolinas fusionadas de heterociclo sustituido.
PT1104760E (pt) 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
US6541639B2 (en) 2000-07-26 2003-04-01 Bristol-Myers Squibb Pharma Company Efficient ligand-mediated Ullmann coupling of anilines and azoles
AU2001292898A1 (en) 2000-09-20 2002-04-02 Brad A. Acker Substituted azepino[4,5b)indole derivatives
US7433168B2 (en) 2000-10-17 2008-10-07 X2Y Attenuators, Llc Amalgam of shielding and shielded energy pathways and other elements for single or multiple circuitries with common reference node
PL366233A1 (en) 2000-12-20 2005-01-24 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
US6759554B2 (en) 2001-04-24 2004-07-06 Massachusetts Institute Of Technology Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
DE10123129A1 (de) 2001-05-02 2002-11-14 Berolina Drug Dev Ab Svedala Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel
WO2003000235A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
US6849640B2 (en) 2001-08-08 2005-02-01 Pharmacia & Upjohn Company Therapeutic 1H-pyrido [4,3-b] indoles
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
EP1314554A1 (fr) 2001-11-23 2003-05-28 Kba-Giori S.A. Dispositif de décollage d'éléments de sécurité
DE10162121A1 (de) 2001-12-12 2003-06-18 Berolina Drug Dev Ab Svedala Deuterierte substituierte Pyrazolyl-Benzolsulfonamide sowie diese Verbindungen enthaltende Arzneimittel
KR100699516B1 (ko) 2002-07-29 2007-03-26 알자 코포레이션 팔리페리돈의 조절 전달을 위한 방법 및 복용 형태
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
KR20050032107A (ko) 2002-08-02 2005-04-06 메사추세츠 인스티튜트 오브 테크놀로지 구리를 촉매로 한 탄소-헤테로원자 결합 및 탄소-탄소결합 형성방법
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
AU2003287433A1 (en) 2002-11-01 2004-06-07 Oregon Health And Science University Treatment of hyperkinetic movement disorder with donepezil
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
PL377426A1 (pl) 2002-12-19 2006-02-06 Bristol-Myers Squibb Company Podstawione tricykliczne gamma-karboliny jako agoniści i antagoniści receptora serotoninowego
DK2009000T3 (da) 2003-01-16 2011-09-05 Acadia Pharm Inc Selektive serotonin 2A/2C-receptor invers-agonister som terapeutika for neurodegenerative sygdomme
AU2004259741A1 (en) 2003-07-21 2005-02-03 Smithkline Beecham Corporation (2S,4S)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof
AR045796A1 (es) 2003-09-26 2005-11-16 Solvay Pharm Bv Derivados de hexa y octahidro - pirido (1,2-a) pirazina con actividad antagonista de nk1. composiciones farmaceuticas.
JP2005259113A (ja) 2004-02-12 2005-09-22 Ricoh Co Ltd プロセス編集装置、プロセス管理装置、プロセス編集プログラム、プロセス管理プログラム、記録媒体、プロセス編集方法及びプロセス管理方法
US20080280941A1 (en) 2004-03-05 2008-11-13 Pierre Lourtie 8-Phenoxy-Gamma Carboline Derivatives
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
US7592454B2 (en) 2004-04-14 2009-09-22 Bristol-Myers Squibb Company Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists
AU2005286943A1 (en) 2004-09-20 2006-03-30 Mount Sinai School Of Medicine Use of memantine (NAMENDA) to treat autism, compulsivity, and impulsivity
JP2008513432A (ja) 2004-09-21 2008-05-01 ファイザー・プロダクツ・インク Cns状態の治療に有用なn−メチルヒドロキシエチルアミン
US7614727B2 (en) 2004-09-30 2009-11-10 Fujifilm Corporation Liquid ejection head, manufacturing method thereof, and image forming apparatus
WO2006063709A1 (en) 2004-12-15 2006-06-22 F.Hoffmann-La Roche Ag Bi- and tricyclic substituted phenyl methanones as glycine transporter i (glyt-1) inhibitors for the treatment of alzheimer’s disease
JP2008528514A (ja) 2005-01-25 2008-07-31 セルジーン・コーポレーション 4−アミノ−2−(3−メチル−2,6−ジオキソピペリジン−3−イル)−イソインドール−1,3−ジオンを使用する方法及び組成物
WO2006081332A1 (en) 2005-01-25 2006-08-03 Epix Delaware, Inc. Substituted arylamine compounds and their use as 5-ht6 modulators
EP1919287A4 (en) 2005-08-23 2010-04-28 Intra Cellular Therapies Inc ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY
CN101309917B (zh) 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+,k+-atp酶氘代抑制剂
WO2007084841A2 (en) 2006-01-13 2007-07-26 Wyeth Sulfonyl substituted 1h-indoles as ligands for the 5-hydroxytryptamine receptors
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
KR102065319B1 (ko) 2007-03-12 2020-01-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
US7612447B2 (en) 2007-06-06 2009-11-03 Gm Global Technology Operations, Inc. Semiconductor devices with layers having extended perimeters for improved cooling and methods for cooling semiconductor devices
WO2009017836A1 (en) 2007-08-01 2009-02-05 Medivation Neurology, Inc. Methods and compositions for treating schizophrenia using antipsychotic combination therapy
ES2668366T3 (es) 2007-08-02 2018-05-17 Insys Development Company, Inc. Pulverización sublingual de fentanilo
WO2009023253A2 (en) 2007-08-15 2009-02-19 Arena Pharmaceuticals Inc. IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
US20090209608A1 (en) 2007-08-29 2009-08-20 Protia, Llc Deuterium-enriched asenapine
US20090076159A1 (en) 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched eplivanserin
AU2009212065B2 (en) 2008-02-05 2014-03-20 Clera Inc. Compositions and methods for alleviating depression or improving cognition
MX2010008688A (es) 2008-02-07 2010-08-30 Schering Corp Anticuerpos anti-receptor de linfopoyetina estromal timica procesados por ingenieria.
JP5611846B2 (ja) * 2008-03-12 2014-10-22 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 置換ヘテロ環縮合ガンマ−カルボリン類固体
CN105168219B (zh) 2008-05-27 2018-11-20 细胞内治疗公司 用于睡眠障碍和其他疾病的方法和组合物
US20100159033A1 (en) 2008-09-29 2010-06-24 Auspex Pharmaceuticals, Inc. Benzisoxazole modulators of d2 receptor, and/or 5-ht2a receptor
WO2011044019A1 (en) 2009-10-05 2011-04-14 Bristol-Myers Squibb Company (R)-1-(4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TRIAZIN-6-YLOXY)PROPAN-2-OL METABOLITES
EP2560676B8 (en) 2010-04-22 2016-10-12 Intra-Cellular Therapies, Inc. Organic compounds
NZ612686A (en) 2010-12-16 2015-11-27 Cynapsus Therapeutics Inc Sublingual films
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
EP2802354A4 (en) 2012-01-09 2015-07-29 Virginia Tech Intell Prop CELLULOSE DERIVATIVES FOR INHIBITING THE CRYSTALLIZATION OF HEAVY WATER-SOLUBLE MEDICAMENTS
WO2013155504A1 (en) 2012-04-14 2013-10-17 Intra-Cellular Therapies, Inc. Novel methods
JP2014074145A (ja) 2012-10-05 2014-04-24 Olympus Corp セルロースナノファイバーとその製造方法、複合樹脂組成物、成形体
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
HUE053159T2 (hu) 2013-03-15 2021-06-28 Intra Cellular Therapies Inc Szerves vegyületek
DK3043777T3 (da) 2013-09-10 2020-07-20 Fresh Cut Dev Llc Sublingual buprenorphinspray
AU2014324837B2 (en) 2013-09-30 2019-01-17 Zoetis Services Llc Long-acting spiro-isoxazoline formulations
IL305990B2 (en) 2013-12-03 2025-12-01 Intra Cellular Therapies Inc Long-acting injectable composition comprising polymeric microspheres of heterocycle fused gamma-carboline compounds or a pharmaceutical composition for sustained or delayed release comprising the compounds and their use in the treatment of bipolar disorder i and/or bipolar ii disorder
MX365969B (es) 2014-04-04 2019-06-21 Intra Cellular Therapies Inc Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio.
RU2016143091A (ru) 2014-04-04 2018-05-08 Интра-Селлулар Терапиз, Инк. Органические соединения
WO2015191554A1 (en) 2014-06-09 2015-12-17 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
JP6537601B2 (ja) 2015-05-12 2019-07-03 大鵬薬品工業株式会社 アザ二環式化合物の結晶
CA3254279A1 (en) * 2015-06-03 2025-03-18 Triastek, Inc. PHARMACEUTICAL FORMS AND RELATED USES
WO2017117514A1 (en) 2015-12-31 2017-07-06 Tung Roger D Deuterated iti-007
US20200392135A1 (en) 2016-03-25 2020-12-17 Intra-Cellular Therapies, Inc. Organic compounds
PL3407889T3 (pl) 2016-03-25 2021-11-22 Intra-Cellular Therapies, Inc. Związki organiczne i ich zastosowanie w leczeniu lub zapobieganiu zaburzeniom ośrodkowego układu nerwowego
US11014925B2 (en) 2016-03-28 2021-05-25 Intra-Cellular Therapies, Inc. Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide
JP2019513143A (ja) 2016-03-28 2019-05-23 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 新規塩類および結晶
EP4001281A1 (en) 2016-08-09 2022-05-25 Teva Pharmaceuticals International GmbH Solid state forms of lumateperone ditosylate salt and preparation thereof
US11331316B2 (en) 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
WO2018106916A1 (en) 2016-12-07 2018-06-14 Concert Pharmaceuticals, Inc. Deuterated quinoxaline compounds
IL268970B2 (en) 2017-03-24 2023-12-01 Intra Cellular Therapies Inc Oral transmucosal formulations of substituted heterocycle fused gamma carbolines
JP2020513023A (ja) * 2017-04-10 2020-04-30 ドクター・レディーズ・ラボラトリーズ・リミテッド ルマテペロンp−トシラートの非晶質形態および固体分散体
JP7223742B2 (ja) * 2017-07-26 2023-02-16 イントラ-セルラー・セラピーズ・インコーポレイテッド 有機化合物
US11655251B2 (en) 2017-11-27 2023-05-23 Egis Gyogyszergyar Zrt. Method for the production of lumateperone and its salts
WO2019178484A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
WO2019183546A1 (en) 2018-03-23 2019-09-26 Intra-Cellular Therapies, Inc. Organic compounds
IL321985A (en) 2018-06-06 2025-09-01 Intra Cellular Therapies Inc New salts and crystals
EP3843729A4 (en) 2018-08-29 2022-06-01 Intra-Cellular Therapies, Inc. NOVEL COMPOSITIONS AND PROCESSES
CN112584837A (zh) * 2018-08-31 2021-03-30 细胞内治疗公司 新方法
CA3108558A1 (en) * 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
US20220024924A1 (en) 2018-11-27 2022-01-27 Teva Czech Industries S.R.O Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof
MX2021006886A (es) * 2018-12-14 2021-09-14 Intra Cellular Therapies Inc Dispersiones solidas amorfas.
JP7673040B2 (ja) 2019-07-07 2025-05-08 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規方法
EP4072554A4 (en) 2019-12-11 2023-12-20 Intra-Cellular Therapies, Inc. ORGANIC CONNECTION
EP4076461B1 (en) 2019-12-19 2026-01-28 Intra-Cellular Therapies, Inc. Lumateperone for use in schizophrenia treatment
JP2025521115A (ja) 2022-05-18 2025-07-08 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規方法

Similar Documents

Publication Publication Date Title
JP2021536453A5 (https=)
JP2021535151A5 (https=)
CN106943355B (zh) 药物组合物
JPWO2020047407A5 (https=)
KR102221846B1 (ko) 안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법
WO2011111818A1 (ja) モサプリドまたはその塩を含む徐放型医薬組成物
TW201639575A (zh) 固形製劑
CA2471715A1 (en) A stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
CA2532485A1 (en) Tablets containing ambroxol
WO2023195955A1 (en) A film coated tablet comprising selexi̇pag and its preparation process
JP2011511818A (ja) フリバンセリンの製剤
EP2394644B1 (en) Trimetazidine Formulation With Different Release Profiles
WO2013100112A1 (ja) アンギオテンシンii拮抗作用を有する化合物を含有する固形医薬組成物
WO2023195957A1 (en) A film coated tablet comprising selexi̇pag processed with wet granulation
JP7641098B2 (ja) リバーロキサバン含有錠剤
WO2020005189A2 (en) Solid oral pharmaceutical compositions comprising teriflunomide
EP2638898A1 (en) Metformin and Pioglitazone Formulation with Different Release Profiles
JP7511596B2 (ja) リバーロキサバン含有錠剤
EP3378479B1 (en) Method for preparing pharmaceutical composition comprising quinoline derivative or salt thereof
KR101068475B1 (ko) 실로스타졸을 포함하는 서방성 제제 및 이의 제조방법
WO2014104989A1 (en) Pharmaceutical compositions comprising aripiprazole
WO2023195954A1 (en) A film coated tablet comprising a solid dispersion of selexi̇pag
DK3166596T3 (en) Pharmaceutical dosage forms
EP3378478B1 (en) Pharmaceutical composition comprising quinoline derivative or salt thereof
WO2013100879A1 (en) Pharmaceutical compositions comprising quetiapine